Aptar Pharma’s new research and development (R&D) centre in Le Vaudreuil and Val-de-Reuil, France, is designed to enhance the development of the company’s drug delivery solutions for patients, clients and consumers worldwide.
The centre became fully operational in July 2025 and was officially inaugurated in September 2025.
Recommended White Papers
Recommended Buyers Guides
The facility is one of 11 global innovation centres operated by Aptar globally and accommodates 170 employees.
The R&D centre enables Aptar Pharma to meet the increasing demand for innovative drug dosing and dispensing solutions across a wide range of therapeutic areas and swiftly address evolving market demands and regulatory standards.
Location
Aptar Pharma’s R&D centre is based in France at the company’s Le Vaudreuil and Val-de-Reuil manufacturing campus.
The location offers convenient access to French and wider regulatory stakeholders in Europe, the Middle East and Africa, enabling closer engagement with bodies such as the European Medicines Agency and helping to align regulatory requirements from the earliest development stages.
The facility is intended to strengthen adherence to European requirements across the product life cycle, including post-market monitoring.
By co-locating design, testing and regulatory expertise near customers, Aptar aims to accelerate response times and support more agile collaboration.
Aptar Pharma R&D centre details
The new R&D centre comprises a two-storey building covering 3,000m2 (32,292ft2) and features open, sky-lit areas.
The facility houses collaborative workspaces to enhance engagement with academic institutions, research consortia and biotechnology companies. These areas are designed to facilitate joint projects and technical knowledge exchange, supporting the advancement of innovative solutions.
The R&D centre is equipped with advanced technologies for device development and utilises digital simulation, rapid prototyping, data analytics, AI and predictive modelling.
These technologies enable teams to assess device performance at an early stage, reducing the need for multiple physical prototypes and shortening the development timeline.
By incorporating rapid prototyping and AI-based optimisation of device design and materials, the centre further streamlines development processes, supporting greater predictability and efficiency.
Research activities at Aptar Pharma’s R&D centre
The new R&D centre increases the capacity to run more programmes concurrently, accelerates the scale-up of promising concepts and shortens the path from idea to industrialisation.
It gives engineers and scientists opportunities to drive high-value innovation within multidisciplinary teams, contributing to the evolution of drug delivery.
By co-locating core competencies with advanced technologies, Aptar Pharma streamlines development cycles and enables evidence-based decision-making.
This configuration strengthens the organisation’s ability to deliver scalable solutions that satisfy therapeutic and operational requirements.
The R&D centre also fosters seamless collaboration and real-time data exchange, enabling integrated approaches to technology and regulatory strategies.
The R&D centre is currently supporting various programmes in nasal and pulmonary drug delivery, platform improvements for chronic respiratory diseases, and emergency-use nasal sprays. It is also engaged in connected devices and the integration of digital health solutions.
Key initiatives include work on a glucagon nasal spray for the treatment of severe hypoglycaemia, and the ZEN30 Futurity valve platform designed for inhalers using low-global-warming-potential propellants.
Sustainable features of the facility
Aptar Pharma’s advanced R&D facility integrates sustainability measures into both its design and operations to reduce energy usage and minimise its environmental footprint.
It is fitted with rooftop solar panels, a heat recovery unit and a rainwater harvesting system, alongside other features that align with Aptar’s sustainable building standards.
The solar panels are expected to supply up to 30% of the building’s total projected electricity needs.
The centre also contributes to Aptar Pharma’s environmental, social and governance objectives by supporting the development of drug delivery solutions that are both effective and environmentally responsible.
Innovations such as recyclable components and metal-free pumps are employed to decrease material waste and enhance product sustainability.
